OliX Pharmaceuticals Statistics

Total Valuation

OliX Pharmaceuticals has a market cap or net worth of KRW 258.43 billion. The enterprise value is 295.60 billion.

Market Cap	258.43B
Enterprise Value	295.60B

Important Dates

The next estimated earnings date is Wednesday, March 19, 2025.

Earnings Date	Mar 19, 2025
Ex-Dividend Date	n/a

Share Statistics

OliX Pharmaceuticals has 18.46 million shares outstanding. The number of shares has increased by 19.09% in one year.

Current Share Class	n/a
Shares Outstanding	18.46M
Shares Change (YoY)	+19.09%
Shares Change (QoQ)	+1.94%
Owned by Insiders (%)	19.53%
Owned by Institutions (%)	13.12%
Float	14.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.31
PB Ratio	14.90
P/TBV Ratio	17.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.68
EV / Sales	18.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.49

Financial Position

The company has a current ratio of 0.42, with a Debt / Equity ratio of 2.88.

Current Ratio	0.42
Quick Ratio	0.35
Debt / Equity	2.88
Debt / EBITDA	n/a
Debt / FCF	-1.39
Interest Coverage	-5.18

Financial Efficiency

Return on equity (ROE) is -87.14% and return on invested capital (ROIC) is -17.44%.

Return on Equity (ROE)	-87.14%
Return on Assets (ROA)	-14.18%
Return on Capital (ROIC)	-17.44%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.17
Inventory Turnover	0.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -6.89% in the last 52 weeks. The beta is 0.66, so OliX Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.66
52-Week Price Change	-6.89%
50-Day Moving Average	19,454.80
200-Day Moving Average	16,826.25
Relative Strength Index (RSI)	32.55
Average Volume (20 Days)	325,868

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OliX Pharmaceuticals had revenue of KRW 16.14 billion and -25.30 billion in losses. Loss per share was -1,534.32.

Revenue	16.14B
Gross Profit	15.89B
Operating Income	-21.04B
Pretax Income	-26.25B
Net Income	-25.30B
EBITDA	-18.41B
EBIT	-21.04B
Loss Per Share	-1,534.32

Full Income Statement

Balance Sheet

The company has 11.87 billion in cash and 48.44 billion in debt, giving a net cash position of -36.57 billion or -1,981.08 per share.

Cash & Cash Equivalents	11.87B
Total Debt	48.44B
Net Cash	-36.57B
Net Cash Per Share	-1,981.08
Equity (Book Value)	16.80B
Book Value Per Share	939.57
Working Capital	-22.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -20.72 billion and capital expenditures -14.12 billion, giving a free cash flow of -34.84 billion.

Operating Cash Flow	-20.72B
Capital Expenditures	-14.12B
Free Cash Flow	-34.84B
FCF Per Share	-1,887.27

Full Cash Flow Statement

Margins

Gross margin is 98.48%, with operating and profit margins of -130.38% and -156.78%.

Gross Margin	98.48%
Operating Margin	-130.38%
Pretax Margin	-162.67%
Profit Margin	-156.78%
EBITDA Margin	-114.06%
EBIT Margin	-130.38%
FCF Margin	n/a

Dividends & Yields

OliX Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.09%
Shareholder Yield	-19.09%
Earnings Yield	-10.96%
FCF Yield	-13.48%

Stock Splits

The last stock split was on December 3, 2020. It was a forward split with a ratio of 2.

Last Split Date	Dec 3, 2020
Split Type	Forward
Split Ratio	2

Scores

OliX Pharmaceuticals has an Altman Z-Score of -1.35. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.35
Piotroski F-Score	n/a